Marwan Fakih, MD

Medical experts discuss how the Inflation Reduction Act’s out-of-pocket prescription drug cost cap, effective in 2025, may impact access to oral chemotherapy options for metastatic colorectal cancer.

Medical experts explore the psychological and emotional aspects of decision-making for patients in the third-line stage of metastatic colorectal cancer, recommend involving support services like social work or palliative care, and discuss the caregiver’s role in supporting patients through these psychosocial challenges.

Medical experts discuss the impact of third-line therapies (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on patient quality of life and share insights on patient adherence to these treatments.

Medical experts compare the toxicity profiles of FTD/TPI plus bevacizumab, regorafenib, and fruquintinib, and discuss practical strategies for managing treatment-related toxicities with these third-line therapies.

Medical experts discuss how to frame the conversation with patients about third-line metastatic colorectal cancer treatment selection, balancing efficacy, safety, and overall prognosis.

Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.

Medical experts discuss additional factors for sequencing therapies such as FTD/TPI plus bevacizumab, fruquintinib, and regorafenib, and identify future research needs for optimizing therapy sequences.

Medical experts highlight key data from the FRESCO-2 trial on fruquintinib for previously treated metastatic colorectal cancer, focusing on study population, efficacy, and safety, and discuss real-world experience with fruquintinib compared with trial outcomes.

Medical experts discuss key takeaways from the SUNLIGHT trial, which compared FTD/TPI monotherapy to FTD/TPI plus bevacizumab for advanced metastatic colorectal cancer, including overall survival, safety, and benefits regardless of prior bevacizumab therapy, and how this data has influenced the use of FTD/TPI in the third-line setting compared with real-world outcomes.

Medical experts review therapy options for metastatic colorectal cancer after FOLFOX/FOLFIRI, emphasizing regorafenib, FTD/TPI plus or minus bevacizumab, and fruquintinib due to the rarity of targetable biomarkers.